What is Axsome Therapeutics's license — revenue?

Axsome Therapeutics (AXSM) reported license — revenue of $0 in Q4 2025.

What does license — revenue mean?

Revenue generated from granting other companies the right to use the firm's intellectual property or technology.

How do you interpret license — revenue?

An increase suggests successful monetization of the R&D pipeline through partnerships, while a decrease may indicate a lack of new licensing deals or the expiration of existing agreements.

How does license — revenue compare across companies?

Common in biopharma companies that utilize a hybrid model of internal commercialization and external out-licensing to generate non-dilutive capital.

Axsome Therapeutics AXSM License — Revenue

Discontinued — last reported Q4 '25

Other product segments

Royalty

$4.07M+269%

Royalty And Milestone Revenue

$1.8M+63.2%

Milestone Revenue

$500K—

Similar metrics at other companies

CYTKLicense — Revenue

$0—

IONSLicense — Revenue

$25M+108%

INSMLicense and Service — Revenue from Contract with Customer, Including Assessed Tax

$1B—

BBIOLicense Revenue — Revenue

$75M—

CYTKLicense And Collaboration — Revenue

$54.86M—

NBIXLicense — Revenue

$15M—

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Axsome Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's license — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's license — revenue?: Axsome Therapeutics (AXSM) reported license — revenue of $0 in Q4 2025.
What does license — revenue mean?: Revenue generated from granting other companies the right to use the firm's intellectual property or technology.
How do you interpret license — revenue?: An increase suggests successful monetization of the R&D pipeline through partnerships, while a decrease may indicate a lack of new licensing deals or the expiration of existing agreements.
How does license — revenue compare across companies?: Common in biopharma companies that utilize a hybrid model of internal commercialization and external out-licensing to generate non-dilutive capital.